A position statement on the management of patients with pityriasis rosea

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 10, 2016, Pages 1670-1681

  Chuh, A ^a   Zawar, V ^b   Sciallis, G ^c   Kempf, W ^d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Godavari Foundation Medical College and Research Center   (India)

^c Mayo Clinic   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZITHROMYCIN; BETAMETHASONE; CETIRIZINE; CLARITHROMYCIN; DEXCHLORPHENIRAMINE; ERYTHROMYCIN;

BREAST FEEDING; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FETUS DEATH; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HEADACHE; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HYPERSENSITIVITY; INTENTION TO TREAT ANALYSIS; NARROW BAND ULTRAVIOLET B PHOTOTHERAPY; NAUSEA; NEONATAL HYPOTONIA; NEWBORN DISEASE; PITYRIASIS ROSEA; PREMATURE LABOR; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SENSITIVITY AND SPECIFICITY; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; ULTRAVIOLET PHOTOTHERAPY;

ACYCLOVIR; HUMANS; PITYRIASIS ROSEA; QUALITY OF LIFE;

EID: 84978906212     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13826     Document Type: Review

References (42)

1. Drago F, Ranieri E, Malaguti F, Losi E, Rebora A. Human herpesvirus 7 in pityriasis rosea. Lancet 1997; 349: 1367–1368.
2. Drago F, Malaguti F, Ranieri E, Losi E, Rebora A. Human herpes virus-like particles in pityriasis rosea lesions: an electron microscopy study. J Cutan Pathol 2002; 29: 359–361.
3. Broccolo F, Drago F, Careddu AM et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol 2005; 124: 1234–1240.
4. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol 2009; 61: 303–318.
5. Rebora A, Drago F, Broccolo F. Pityriasis rosea and herpesviruses: facts and controversies. Clin Dermatol 2010; 28: 497–501.
6. Drago F, Ciccarese G, Rebora A, Parodi A. Relapsing pityriasis rosea. Dermatology 2014; 229: 316–318.
7. Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology 2015; 230: 23–26.
8. Kempf W, Adams V, Kleinhans M et al. Pityriasis rosea is not associated with human herpesvirus 7. Arch Dermatol 1999; 135: 1070–1072.
9. Chuh AA, Chiu SS, Peiris JS. Human herpesvirus 6 and 7 DNA in peripheral blood leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: a prospective case control study. Acta Derm Venereol 2001; 81: 289–290.
10. Yildirim M, Aridogan BC, Baysal V, Inaloz HS. The role of human herpes virus 6 and 7 in the pathogenesis of pityriasis rosea. Int J Clin Pract 2004; 58: 119–121.
11. Franti M, Gessain A, Darlu P et al. Genetic polymorphism of human herpesvirus-7 among human populations. J Gen Virol 2001; 82: 3045–3050.
12. Miranda SM, Porto LC, Pontes LF, Filgueira AL. Correlation between HLA and pityriasis rosea susceptibility in Brazilian blacks. J Eur Acad Dermatol Venereol 2006; 20: 21–26.
13. Chuh AAT, Chan HHL. The effect on quality of life in patients with pityriasis rosea – is it associated with rash severity? Int J Dermatol 2005; 44: 372–377.
14. Chuh AAT. Quality of life in children with pityriasis rosea – a prospective case control study. Pediatr Dermatol 2003; 20: 474–478.
15. Chuh AA, Au TS. Pityriasis rosea – a review of the specific treatments. Proc R Coll Physicians Edinb 2001; 31: 203–207.
16. Chuh AA, Dofitas B, Comisel G et al. Interventions for pityriasis rosea. Cochrane Database Syst Rev 2007; 2: CD005068.
17. Chuh A, Dofitas B, Comisel G, Reveiz L, Sharma V, Chu V. Interventions for pityriasis rosea – a protocol. Ninth Cochrane Dermatology Meeting. Headquarters, British Association of Dermatologists, London, 2004.
18. Berger VW. A review of methods for ensuring the comparability of comparison groups in randomized clinical trials. Rev Recent Clin Trials 2006; 1: 81–86.
19. Zhu QY. The observation of curative effects of glycyrrhizin in treating pityriasis rosea. J Clin Dermatol 1992; 21: 43.
20. Leenutaphong V, Jiamton S. UVB phototherapy for pityriasis rosea: a bilateral comparison study. J Am Acad Dermatol 1995; 33: 996–999.
21. Lazaro-Medina A, Villena-Amurao C, Dy-Chua NS. A clinicohistopathologic study of a randomized double-blind clinical trial using oral dexchlorpheniramine 4 mg, betamethasone 500 mcg and betamethasone 250 mcg with dexchlorpheniramine 2 mg in the treatment of pityriasis rosea: a preliminary report. J Philippine Dermatological Soc 1996; 5: 3–7.
22. Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L. Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2000; 42: 241–244.
23. Rasi A, Tajziehchi L, Savabi-Nasab S. Oral erythromycin is ineffective in the treatment of pityriasis rosea. J Drugs Dermatol 2008; 7: 35–38.
24. Ehsani A, Esmaily N, Noormohammadpour P, Toosi S. The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea. Indian J Dermatol 2010; 55: 246–248.
25. Amatya A, Rajouria EA, Karn DK. Comparative study of effectiveness of oral acyclovir with oral erythromycin in the treatment of Pityriasis rosea. Kathmandu Univ Med J (KUMJ) 2012; 10: 57–61.
26. Ahmed N, Iftikhar N, Bashir U, Rizvi SSD, Sheikh ZI, Manzur A. Efficacy of clarithromycin in pityriasis rosea. J Coll Physicians Surg Pak 2014; 24: 802–805.
27. Jairath V, Mohan M, Jindal N et al. Narrowband UVB phototherapy in pityriasis rosea. Indian Dermatol Online J 2015; 6: 326–329.
28. Rassai S, Feily A, Sina N, Abtahian S. Low dose of acyclovir may be an effective treatment against pityriasis rosea: a random investigator-blind clinical trial on 64 patients. J Eur Acad Dermatol Venereol 2011; 25: 24–26.
29. Pandhi D, Singal A, Verma P, Sharma R. The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial. Indian J Dermatol Venereol Leprol 2014; 80: 36–40.
30. Ganguly S. A randomized, double-blind, placebo-controlled study of efficacy of oral acyclovir in the treatment of pityriasis rosea. J Clin Diagn Res 2014; 8: YC01–YC04.
31. Das A, Sil A, Das NK, Roy K, Das AK, Bandyopadhyay D. Acyclovir in pityriasis rosea: an observer-blind, randomized controlled trial of effectiveness, safety and tolerability. Indian Dermatol Online J 2015; 6: 181–184.
32. Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol 2006; 54: 82–85.
33. Jang YJ, Wang JH, Kim JS, Kwon HJ, Yeo NK, Lee BJ. Levocetirizine inhibits rhinovirus-induced ICAM-1 and cytokine expression and viral replication in airway epithelial cells. Antiviral Res 2009; 81: 226–233.
34. Drago F, Broccolo F, Zaccaria E et al. Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol 2008; 58: S78–S83.
35. Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A. Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea. J Am Acad Dermatol 2014; 71: 198–199.
36. Drago F, Ciccarese G, Rebora A, Parodi A. The efficacy of macrolides and acyclovir in pityriasis rosea. Indian J Dermatol Venereol Leprol 2015; 81: 56.
37. Chuh AAT. Diagnostic criteria for pityriasis rosea – a prospective case control study for assessment of validity. J Eur Acad Dermatol Venereol 2003; 17: 101–103.
38. Zawar V, Chuh A. Follicular pityriasis rosea – case report and a new classification of clinical variants of the disease. J Dermatol Case Rep 2012; 6: 36–39.
39. Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A. Pityriasis rosea: a comprehensive classification. Dermatology 2016. [Epub ahead of print].
40. Cochrane Skin Group. Methods used in reviews. [WWW document]. URL http://skin.cochrane.org/methods-used-reviews (last accessed: 5 May 2016).
41. European Dermatology Forum. SOP for creation of European Dermatology Guidelines. [WWW document]. URL http://euroderm.org/edf/index.php/edf-guidelines/category/9-sops?download=54:sop-for-creation-of-european-dermatology-guidelines (last accessed: 5 May 2016).
42. Chuh A. Pityriasis rosea – roles of the dermatology nurse. Dermatol Nurs 2004; 16: 130–134.